REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Ziff, M. [1 ]
Cheesman, S. [1 ]
Kyriakou, C. [1 ]
Mehta, A. [1 ]
Papanikolaou, X. [1 ]
Rabin, N. [1 ]
Wechalekar, A. [1 ]
Yong, K. [1 ]
Popat, R. [1 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1975
引用
收藏
页码：786 / 787
页数：2
相关论文
共 50 条
  • [31] Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    Bakirtas, Mehmet
    Dal, Mehmet Sinan
    Yigenoglu, Tugce Nur
    Giden, Asli Odabasi
    Serin, Istemi
    Basci, Semih
    Kalpakci, Yasin
    Korkmaz, Serdal
    Ekinci, Omer
    Albayrak, Murat
    Basturk, Abdulkadir
    Ozatli, Duzgun
    Dogu, Mehmet Hilmi
    Hacibekiroglu, Tuba
    Cakar, Merih Kizil
    Ulas, Turgay
    Miskioglu, Mine
    Gulturk, Emine
    Eser, Bulent
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (06) : 563 - 569
  • [32] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary E.
    Feng, Huaibao
    Brun, Nikolai Constantin
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [33] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
    Plesner, T.
    Arkenau, H. T.
    Lokhorst, H. M.
    Gimsing, P.
    Krejcik, J.
    Lemech, C.
    Minnema, M. C.
    Lassen, U.
    Ahmadi, T.
    Yeh, H.
    Guckert, M.
    Brun, N. C.
    Lisby, S.
    Basse, L.
    Palumbo, A.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 104 - 104
  • [34] Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study
    Clement-Filliatre, Lauriane
    Benboubker, Lotfi
    Stoppa, Anne-Marie
    Rodon, Philippe
    Laribi, Kamel
    Vincent, Laure
    Collet, Philippe
    Richez, Valentine
    Charvet-Rumpler, Anne
    Zerazhi, Hacene
    Hulin, Cyrille
    Maloisel, Frederic
    Macro, Margaret
    Karlin, Lionel
    Texier, Nathalie
    Chouaid, Christos
    Leleu, Xavier
    BLOOD, 2020, 136
  • [35] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Jiri Minarik
    Tomas Pika
    Jakub Radocha
    Alexandra Jungova
    Jan Straub
    Tomas Jelinek
    Ludek Pour
    Petr Pavlicek
    Martin Mistrik
    Lucie Brozova
    Petra Krhovska
    Katerina Machalkova
    Pavel Jindra
    Ivan Spicka
    Hana Plonkova
    Martin Stork
    Jaroslav Bacovsky
    Lenka Capkova
    Michal Sykora
    Petr Kessler
    Lukas Stejskal
    Adriana Heindorfer
    Jana Ullrychova
    Tomas Skacel
    Vladimir Maisnar
    Roman Hajek
    BMC Cancer, 21
  • [36] Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Skacel, Tomas
    Maisnar, Vladimir
    Hajek, Roman
    BMC CANCER, 2021, 21 (01)
  • [37] EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE
    Soyer, N.
    Patir, P.
    Uysal, A.
    Duran, M.
    Unal, H. D.
    Tombuloglu, M.
    Sahin, F.
    Vural, F.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S36 - S36
  • [38] Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
    Zherebtsova, Vera A.
    Vorobyev, Vladimir, I
    Gemdzhian, Eduard G.
    Ulyanova, Margarita A.
    Chernikov, Mikhail, V
    Ivanova, Valentina L.
    Vinogradova, Olga Yu
    Ptushkin, Vadim V.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (07) : 785 - 792
  • [39] Ixazomib/Lenalidomide/Dexamethasone (IRd) in relapsed refractory Multiple Myeloma (RRMM) - retrospective real-world data from Germany and comparison to literature
    Roesner, A.
    Wenger, S.
    Brioli, A.
    von Lilienfeld-Toal, M.
    Klaiber-Hakimi, M.
    Fehr, E. M.
    Munder, M.
    Epp, K.
    Trautmann-Grill, K.
    Engelhardt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 235 - 236
  • [40] Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Palumbo, Antonio
    Dimopoulos, Meletios
    San Miguel, Jesus
    Harousseau, Jean-Luc
    Attal, Michel
    Hussein, Mohamad
    Knop, Stefan
    Ludwig, Heinz
    von Lilienfeld-Toal, Marie
    Sonneveld, Pieter
    BLOOD REVIEWS, 2009, 23 (02) : 87 - 93
12345